Apellis Pharmaceuticals, Inc. (APLS) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, ladies and gentlemen. Thank you for standing by, and welcome to the Appellate Pharmaceuticals Third Quarter 2025 Earnings Conference Call. Please be advised that today's conference is being recorded. I would now like to turn the call over to Evel Straynoski, Head of Investor Relations. Please go ahead. Good morning, and thank you for joining us to discuss Appellate's Third Quarter 2025 Financial Results. With me on the call are co-founder and Chief Executive Officer, Dr. Cedric Francois, Executive Vice President of Commercials, David Atchison, Chief Medical Officer, Dr. Caroline Baumel, and Chief Financial Officer, Tim Sullivan. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings for additional detail. Now, I'll turn the call over to Cedric. Thank you, Eva. Before diving into our third quarter results and portfolio progress, I want to briefly highlight the unmet need that Aperis set out to tackle and why we are uniquely positioned to address that challenge. Aperis is a commercial stage biotech company targeting the over-activation of the complement system an innate defense mechanism in the immune system that protects the body from acute infection and illness. However, when complement is chronically unregulated, there can be a devastating effect on one's health, driving a broad range of serious, often life-threatening diseases. Most approved complement targeted therapeutics inhibit at C5, a downstream protein in the complement cascade. By only blocking this target, T5 inhibitors do not affec...